Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Anomaly is an innovative AI-driven platform designed for payer management that empowers healthcare revenue teams to understand their payers as thoroughly as those payers understand them. By revealing hidden behaviors of payers through the analysis of intricate rules and payment trends across millions of healthcare interactions, it enhances operational efficiency. Central to this platform is its Smart Response engine, which perpetually scrutinizes payer logic, adjusts to evolving policies, and integrates its insights into current revenue cycle processes, enabling real-time predictions of denials, support in claims adjustments, and alerts regarding potential revenue threats. Users gain the ability to foresee revenue shortfalls, negotiate more effectively with payers, and proactively address or overturn denials, thereby safeguarding cash flow. This advanced system effectively bridges the gap between providers and payers, transforming complex billing frameworks into practical intelligence that informs daily financial management while also fostering an environment of enhanced strategic decision-making for revenue teams. By empowering users with this level of insight, Anomaly not only improves operational outcomes but also contributes to a more equitable balance in the healthcare financial landscape.
Description
Introducing a versatile API designed to seamlessly integrate with your diabetes management system, offering tailored therapeutic education and enhanced insights into blood glucose level fluctuations. This solution enables real-time risk predictions, fostering greater personalization and improved system regulation, while adeptly managing complex living scenarios characterized by rapid glucose variations. With advancements in telemedicine and retrospective analysis, patients receive robust decision-support tools. Currently, Hillo is developing the next iterations of its AI technology, which includes a therapeutic recommendation system aimed at preventing hypoglycemia and hyperglycemia, anticipated to achieve CE mark class IIB by 2020. Additionally, a new generation of the artificial pancreas is projected for release in 2021, addressing key limitations of existing systems through ultra-personalization driven by machine learning. This innovative approach marks the introduction of the first self-learning artificial intelligence capable of predicting blood glucose levels, aiming to secure a CE mark as a medical device, thereby transforming diabetes management for users. In essence, Hillo's advancements could significantly enhance the quality of life for individuals managing diabetes.
API Access
Has API
No
API Access
Has API
Yes
Integrations
No details available.
Integrations
No details available.
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Pricing Details
No price information available.
Free Trial
Yes
Free Version
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Types of Training
Training Docs
Yes
Webinars
No
Live Training (Online)
Yes
In Person
No
Types of Training
Training Docs
Yes
Webinars
No
Live Training (Online)
No
In Person
Yes
Vendor Details
Company Name
Anomaly
Founded
2020
Country
United States
Website
www.findanomaly.com
Vendor Details
Company Name
Hillo
Country
France
Website
www.hillo.ai/